Disease Landscape and Forecast Insights

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…

Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…

Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…